市場調查報告書

用於COPD和哮喘的醫療器械全球市場:按產品類型,指示和分銷渠道進行的機會分析和行業預測:2020-2027

COPD and Asthma Devices Market by Product Type (Inhalers and Nebulizers), Indication (Asthma and COPD), and Distribution Channel (Retail Pharmacies, Hospitals, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast 2020-2027

出版商 Allied Market Research 商品編碼 951375
出版日期 內容資訊 英文 276 Pages
商品交期: 2-3個工作天內
價格
用於COPD和哮喘的醫療器械全球市場:按產品類型,指示和分銷渠道進行的機會分析和行業預測:2020-2027 COPD and Asthma Devices Market by Product Type (Inhalers and Nebulizers), Indication (Asthma and COPD), and Distribution Channel (Retail Pharmacies, Hospitals, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast 2020-2027
出版日期: 2020年06月01日內容資訊: 英文 276 Pages
簡介

到2027年,用於治療慢性阻塞性肺疾病(COPD)和哮喘的醫療設備的全球市場預計將達到516,628.50萬美元,從2020年到2027年的複合年增長率為4.30%。 COPD和用於治療哮喘的醫療設備在向肺部輸送藥物方面發揮著作用,並被用於呼吸道疾病和其他相關疾病的連續治療和緊急治療。 COPD和哮喘在全球呼吸系統疾病中佔很大比例,根據世界衛生組織(WHO)的數據,2016年COPD病例數約為2.51億。因此,已經開發了各種藥物遞送方法,例如口服和腸胃外,但是與其他方法相比,將藥物遞送到肺部的系統被認為是最有效的方法。市場增長將受到人們對呼吸系統疾病(如哮喘和肺氣腫)的日益關注的驅使,由於菸草消費引起的呼吸系統疾病的發病率增加,醫療費用增加,以及醫療機構的自動化程度提高,先進醫療解決方案的迅速普及等因素。

本報告調查了用於治療COPD和哮喘的醫療設備的全球市場,包括市場概況,產品類型,適應症,分銷渠道,區域分析,競爭格局和主要公司。

內容

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
  • 波特的五力分析
  • 價值鏈分析
  • 政府法規
    • 歐美COPD醫療器械法規
    • 亞太地區COPD醫療器械法規
  • 臨床試驗
  • 專利分析
  • 促進增長的因素
    • 常規暴露於環境污染中
    • 易受室內空氣污染物影響的人口增加
    • 藥物輸送裝置的便攜性
    • 吸煙人口增加
    • 政府舉措
  • 成長阻害要因
    • 價格競爭和材料質量下降
    • 哮喘治療的總體費用高昂
    • 兌換支持不足
  • 市場機會
    • 重磅炸彈藥物專利已過期
    • 智能吸入器:未來增長因素

第4章市場分析:按產品

  • 概述
    • 市場規模和預測
  • 吸入器
    • 藥物粉末吸入器(DPI)
    • 計量吸入器(MDI)
    • 軟霧吸入器
  • 霧化器
    • 壓縮機霧化器
    • 超聲波霧化器
    • 網狀霧化器

第5章按指標進行市場分析

  • 概述
    • 市場規模和預測
  • 哮喘
  • COPD

第6章市場分析:按分銷渠道

  • 概述
    • 市場規模和預測
  • 零售藥房
  • 醫院
  • 在線藥房

第7章按地區進行市場分析

  • 概述
    • 市場規模和預測
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 俄羅斯
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 阿根廷
    • 沙特阿拉伯
    • 哥倫比亞
    • 土耳其
    • 其他

第8章公司簡介

  • Aerogen, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • GF Health Products, Inc.
  • GlaxoSmithKline Plc
  • Koninklijke Philips N.V. (Philips)
  • Novartis AG
  • PARI medical Holding GMBH
  • Smith's Group Plc
目錄
Product Code: A00469

The global COPD and asthma devices market is expected to reach $51,628.58 million by 2027, registering a CAGR of 4.30% during 2020-2027.

Chronic obstructive pulmonary disease (COPD) and asthma devices, also known as pulmonary drug delivery devices, are used as a permanent treatment or rescue therapy for respiratory diseases and other related ailments. It is the most advanced mode of drug administration in which the drug is directly delivered to the lungs to provide a systemic effect. COPD and asthma have significant shares in the global respiratory diseases market. According to the Global Health Organization (WHO), in 2016, around 251 million cases of COPD were estimated globally. Thus, a variety of drug-delivery protocols, such as oral and parenteral delivery, are developed for the treatment of COPD and asthma. However, the pulmonary drug delivery system is the most effective treatment option as compared to the other conventional methods.

The major factors that drive the market growth are increase in concerns of respiratory diseases, such as asthma and emphysema, and rise in incidences of respiratory diseases caused due to cigarette consumption. Furthermore, increase in healthcare expenditure, growth in use of automation in the healthcare industry, and rapid adoption of advanced medical solutions also boost the market growth. Currently, most of healthcare practitioners and pulmonary diseases specialists prefer a combination of a drug and a device, for instance, inhaler and nebulizer, owing to its fast and effective outcome. However, the factors such as high cost associated with nebulizers, side effects occurring due to excessive dosage, and lack of awareness regarding the drug inhalation are expected to restrain the growth of the market. On the contrary, introduction of smart inhaler drives the opportunity for the growth of COPD and asthma devices market in near future.

The global COPD and asthma devices market is segmented on the basis of product type, indication, distributional channel, and region. Based on the device type, the market is segmented into inhalers and nebulizers. Furthermore, the inhalers segment includes dry powder inhalers (DPIs), metered dose inhalers (MDIs), and soft mist inhalers (SMIs). However, the nebulizers segment includes compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers. Based on indication, the market is divided into asthma and COPD. Based on distribution channel, it is segregated into retail pharmacies, online pharmacies, and hospitals. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. These regions are further analyzed on the basis of respective countries.

The leading players profiled in this report include Aerogen, Inc., AstraZeneca PLC, Baxter International Inc., Boehringer Ingelheim International GmbH, 3M COMPANY, GF Health Products, GlaxoSmithKline Plc, Koninklijke Philips N.V., Novartis AG, PARI Medical Holding GMBH, and Smith's Group Plc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

Key Market Segments

By Product Type

  • Inhalers
  • Drug Powder Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
  • Soft Mist Inhalers (SMIs)
  • Nebulizers
  • Compressor Nebulizers
  • Ultrasonic Nebulizers
  • Mesh Nebulizers

By Indication

  • Asthma
  • COPD

By Distribution Channel

  • Retail Pharmacies
  • Hospitals
  • Online Pharmacies
  • By Region
  • North America
  • § U.S.
  • § Canada
  • § Mexico
  • Europe
  • § Germany
  • § France
  • § UK
  • § Italy
  • § Russia
  • § Rest of Europe
  • Asia-Pacific
  • § Japan
  • § China
  • § India
  • § Australia
  • § Rest of Asia-Pacific
  • Middle East
  • § Saudi Arabia
  • § Brazil
  • § Argentina
  • § Colombia
  • § Turkey
  • § Rest of LAMEA
  • List of key players profiled in the report
  • Aerogen, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • 3M COMPANY
  • GF Health Products
  • GlaxoSmithKline Plc
  • Koninklijke Philips N.V.
  • Novartis AG
  • PARI Medical Holding GMBH
  • Smith's Group Plc.
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
  • Lincare Holdings Inc
  • Allied Healthcare Products Inc
  • Sunovion Pharmaceuticals Inc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Primary research
    • 1.4.2.Secondary Research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.key findings of the study:
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top impacting factors
    • 3.2.2.Top investment pockets
    • 3.2.3.Top winning strategies, 2016-2018
  • 3.3.Porter's five forces analysis
    • 3.3.1.Moderate bargaining power of buyers
    • 3.3.2.Low bargaining power of suppliers
    • 3.3.3.Moderate threat of substitutes
    • 3.3.4.Low threat of new entrants
    • 3.3.5.Moderate competitive rivalry
  • 3.4.Value chain analysis
  • 3.5.Government regulations
    • 3.5.1.COPD devices regulations in Europe and in the U.S.
    • 3.5.2.COPD devices regulations in Asia-Pacific
  • 3.6.Clinical trials
  • 3.7.Patent analysis
    • 3.7.1.Patent analysis by region
    • 3.7.2.U.S. Patent analysis
    • 3.7.3.Europe patent analysis
    • 3.7.4.Japan patent analysis
  • 3.8.Drivers
    • 3.8.1.Daily exposure to environmental pollution
    • 3.8.2.Increase in population susceptible to indoor air pollutants
    • 3.8.3.Portability of the drug delivery devices
    • 3.8.4.Increasing population of active smokers
    • 3.8.5.Rising government initiatives
  • 3.9.Restraints
    • 3.9.1.Increase in price competition and deterioration of material quality
    • 3.9.2.Overall high cost of asthma treatment is a challenge for the patients
    • 3.9.3.Incompetent reimbursement support
  • 3.10.Opportunities
    • 3.10.1.Patent expiration for blockbuster drugs
    • 3.10.2.Smart Inhaler: future growth driver

CHAPTER 4:COPD AND ASTHMA DEVICES MARKET, BY PRODUCT

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Inhalers
    • 4.2.1.Market size and forecast
    • 4.2.2.Market share analysis, by country
    • 4.2.3.Drug powdered inhalers (DPIs)
      • 4.2.3.1.Key market trends and opportunity
    • 4.2.4.Metered dose inhalers (MDIs)
      • 4.2.4.1.Key market trends and opportunity
    • 4.2.5.Soft mist inhalers
      • 4.2.5.1.Key market trends and opportunity
  • 4.3.Nebulizers
    • 4.3.1.Market size and forecast
    • 4.3.2.Market share analysis, by country
      • 4.3.2.1.Compressor nebulizers
      • 4.3.2.2.Ultrasonic nebulizers
      • 4.3.2.3.Mesh nebulizers

CHAPTER 5:COPD AND ASTHMA DEVICES MARKET, BY INDICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Asthma
    • 5.2.1.Market size and forecast
    • 5.2.2.Market share analysis, by country
  • 5.3.COPD
    • 5.3.1.Market size and forecast
    • 5.3.2.Market share analysis, by country

CHAPTER 6:COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Retail Pharmacies
    • 6.2.1.Market size and forecast
    • 6.2.2.Market share analysis, by country
  • 6.3.Hospitals
    • 6.3.1.Market size and forecast
    • 6.3.2.Market share analysis, by country
  • 6.4.Online Pharmacies
    • 6.4.1.Market size and forecast
    • 6.4.2.Market share analysis, by country

CHAPTER 7:COPD & ASTHMA DEVICE MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends and opportunities
    • 7.2.2.North America market size and forecast, by country
    • 7.2.3.North America market size and forecast, by product
    • 7.2.4.North America market size and forecast, by indication
    • 7.2.5.North America market size and forecast, by distribution channel
      • 7.2.5.1.U.S.
      • 7.2.5.1.1.U.S. market size and forecast, by product
      • 7.2.5.1.2.U.S. market size and forecast, by indication
      • 7.2.5.1.3.U.S. market size and forecast, by distribution channel
      • 7.2.5.2.Canada
      • 7.2.5.2.1.Canada market size and forecast, by product
      • 7.2.5.2.2.Canada market size and forecast, by indication
      • 7.2.5.2.3.Canada market size and forecast, by distribution channel
      • 7.2.5.3.Mexico
      • 7.2.5.3.1.Mexico market size and forecast, by product
      • 7.2.5.3.2.Mexico market size and forecast, by indication
      • 7.2.5.3.3.Mexico market size and forecast, by distribution channel
  • 7.3.Europe
    • 7.3.1.Key market trends and opportunities
    • 7.3.2.Europe market size and forecast, by country
    • 7.3.3.Europe market size and forecast, by product
    • 7.3.4.Europe market size and forecast, by indication
    • 7.3.5.Europe market size and forecast, by distribution channel
      • 7.3.5.1.Germany
      • 7.3.5.1.1.Germany market size and forecast, by product
      • 7.3.5.1.2.Germany market size and forecast, by indication
      • 7.3.5.1.3.Germany market size and forecast, by distribution channel
      • 7.3.5.2.UK
      • 7.3.5.2.1.UK market size and forecast, by product
      • 7.3.5.2.2.UK market size and forecast, by indication
      • 7.3.5.2.3.UK market size and forecast, by distribution channel
      • 7.3.5.3.France
      • 7.3.5.3.1.France market size and forecast, by product
      • 7.3.5.3.2.France market size and forecast, by indication
      • 7.3.5.3.3.France market size and forecast, by distribution channel
      • 7.3.5.4.Italy
      • 7.3.5.4.1.Italy market size and forecast, by product
      • 7.3.5.4.2.Italy market size and forecast, by indication
      • 7.3.5.4.3.Italy market size and forecast, by distribution channel
      • 7.3.5.5.Russia
      • 7.3.5.5.1.Russia market size and forecast, by product
      • 7.3.5.5.2.Russia market size and forecast, by indication
      • 7.3.5.5.3.Russia market size and forecast, by distribution channel
      • 7.3.5.6.Rest of Europe
      • 7.3.5.6.1.Rest of Europe market size and forecast, by product
      • 7.3.5.6.2.Rest of Europe market size and forecast, by indication
      • 7.3.5.6.3.Rest of Europe market size and forecast, by distribution channel
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends and opportunities
    • 7.4.2.Asia-Pacific market size and forecast, by country
    • 7.4.3.Asia-Pacific market size and forecast, by product
    • 7.4.4.Asia-Pacific market size and forecast, by indication
    • 7.4.5.Asia-Pacific market size and forecast, by distribution channel
      • 7.4.5.1.Japan
      • 7.4.5.1.1.Japan market size and forecast, by product
      • 7.4.5.1.2.Japan market size and forecast, by indication
      • 7.4.5.1.3.Japan market size and forecast, by distribution channel
      • 7.4.5.2.China
      • 7.4.5.2.1.China market size and forecast, by product
      • 7.4.5.2.2.China market size and forecast, by indication
      • 7.4.5.2.3.China market size and forecast, by distribution channel
      • 7.4.5.3.India
      • 7.4.5.3.1.India market size and forecast, by product
      • 7.4.5.3.2.India market size and forecast, by indication
      • 7.4.5.3.3.India market size and forecast, by distribution channel
      • 7.4.5.4.Australia
      • 7.4.5.4.1.Australia market size and forecast, by product
      • 7.4.5.4.2.Australia market size and forecast, by indication
      • 7.4.5.4.3.Australia market size and forecast, by distribution channel
      • 7.4.5.5.Rest of Asia-Pacific
      • 7.4.5.5.1.Rest of Asia-Pacific market size and forecast, by product
      • 7.4.5.5.2.Rest of Asia-Pacific market size and forecast, by indication
      • 7.4.5.5.3.Rest of Asia-Pacific market size and forecast, by distribution channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends and opportunities
    • 7.5.2.LAMEA market size and forecast, by country
    • 7.5.3.LAMEA market size and forecast, by product
    • 7.5.4.LAMEA market size and forecast, by indication
    • 7.5.5.LAMEA market size and forecast, by distribution channel
      • 7.5.5.1.Brazil
      • 7.5.5.1.1.Brazil market size and forecast, by product
      • 7.5.5.1.2.Brazil market size and forecast, by indication
      • 7.5.5.1.3.Brazil market size and forecast, by distribution channel
      • 7.5.5.2.Argentina
      • 7.5.5.2.1.Argentina market size and forecast, by product
      • 7.5.5.2.2.Argentina market size and forecast, by indication
      • 7.5.5.2.3.Argentina market size and forecast, by distribution channel
      • 7.5.5.3.Saudi Arabia
      • 7.5.5.3.1.Saudi Arabia market size and forecast, by product
      • 7.5.5.3.2.Saudi Arabia market size and forecast, by indication
      • 7.5.5.3.3.Saudi Arabia market size and forecast, by distribution channel
      • 7.5.5.4.Colombia
      • 7.5.5.4.1.Colombia market size and forecast, by product
      • 7.5.5.4.2.Colombia market size and forecast, by indication
      • 7.5.5.4.3.Colombia market size and forecast, by distribution channel
      • 7.5.5.5.Turkey
      • 7.5.5.5.1.Turkey market size and forecast, by product
      • 7.5.5.5.2.Turkey market size and forecast, by indication
      • 7.5.5.5.3.Turkey market size and forecast, by distribution channel
      • 7.5.5.6.Rest of LAMEA
      • 7.5.5.6.1.Rest of LAMEA market size and forecast, by product
      • 7.5.5.6.2.Rest of LAMEA market size and forecast, by indication
      • 7.5.5.6.3.Rest of LAMEA market size and forecast, by distribution channel

CHAPTER 8:COMPANY PROFILES

  • 8.1.Aerogen, Inc.
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Product portfolio
  • 8.2.AstraZeneca PLC
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
    • 8.2.6.Key strategic moves and developments
  • 8.3.Baxter International Inc.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product Portfolio
    • 8.3.5.Business performance
  • 8.4.Boehringer Ingelheim International GmbH
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
    • 8.5.3M COMPANY
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
    • 8.5.6.Key strategic moves and developments
  • 8.6.GF Health Products, Inc.
    • 8.6.1.Company overview
    • 8.6.2.Product portfolio
  • 8.7.GlaxoSmithKline Plc
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
    • 8.7.6.Key strategic moves and developments
  • 8.8.Koninklijke Philips N.V. (Philips)
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.Novartis AG
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
    • 8.9.6.Key strategic moves and developments
  • 8.10.PARI medical Holding GMBH
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Key strategic moves and developments
  • 8.11.Smith's Group Plc
    • 8.11.1.Company overview
    • 8.11.2.Company snapshot
    • 8.11.3.Operating business segments
    • 8.11.4.Product portfolio
    • 8.11.5.Business performance

LIST OF TABLES

  • TABLE 01.CLINICAL TRIALS - COPD AND ASTHMA DEVICES
  • TABLE 02.COPD AND ASTHMA DEVICES PATENTS
  • TABLE 03.ADVANTAGES AND DISADVANTAGES OF MARKETED PORTABLE INHALER DEVICES
  • TABLE 04.PERCENTAGE OF SMOKER POPULATION BY RACE/ETHNICITY, 2016
  • TABLE 05.COST OF ASTHMA IN BILLION, 2015
  • TABLE 06.COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 07.RESCUE INHALERS VS MAINTENANCE INHALERS
  • TABLE 08.COMMON TYPES OF INHALERS
  • TABLE 09.TOP 10 COPD INHALERS
  • TABLE 10.INHALERS COPD AND ASTHMA DEVICES MARKET, BY REGION 2019-2027, ($MILLION)
  • TABLE 11.DRY POWDER INHALERS
  • TABLE 12.TYPES OF METERED DOSE INHALERS (MDIS)
  • TABLE 13.COMMERCIALIZED NEBULIZERS AND ITS COST
  • TABLE 14.NEBULIZERS COPD AND ASTHMA DEVICES MARKET, BY REGION 2019-2027, ($MILLION)
  • TABLE 15.COPD AND ASTHMA DEVICES MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 16.ASTHMA COPD ANDS ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 17.COPD AND ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 18.COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 19.RETAIL PHARMACIES COPD AND ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 20.HOSPITALS COPD AND ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 21.ONLINE PHARMACIES COPD AND ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 22.GLOBAL COPD AND ASTHMA DEVICES MARKET, BY REGION 2019-2027 ($MILLION)
  • TABLE 23.NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 24.NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 25.NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 26.NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 27.U.S. COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 28.U.S. COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 29.U.S. COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 30.CANADA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 31.CANADA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 32.CANADA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 33.MEXICO COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 34.MEXICO COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 35.MEXICO COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 36.EUROPE COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 37.EUROPE COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 38.EUROPE COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 39.GERMANY COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 40.GERMANY COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 41.GERMANY COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 42.UK COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 43.UK COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 44.UK COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 45.FRANCE COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 46.FRANCE COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 47.FRANCE COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 48.ITALY COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 49.ITALY COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 50.ITALY COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 51.RUSSIA COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 52.RUSSIA COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 53.RUSSIA COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 54.REST OF EUROPE COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 55.REST OF EUROPE COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 56.REST OF EUROPE COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 57.ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 58.ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 59.ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 60.ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 61.JAPAN COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 62.JAPAN COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 63.JAPAN COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 64.CHINA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 65.CHINA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 66.CHINA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 67.INDIA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 68.INDIA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 69.INDIA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 70.AUSTRALIA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 71.AUSTRALIA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 72.AUSTRALIA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 73.REST OF ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 74.REST OF ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 75.REST OF ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 76.LAMEA COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 77.LAMEA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 78.LAMEA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 79.LAMEA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 80.BRAZIL COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 81.BRAZIL COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 82.BRAZIL COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 83.ARGENTINA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 84.ARGENTINA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 85.ARGENTINA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 86.SAUDI ARABIA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 87.SAUDI ARABIA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 88.SAUDI ARABIA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 89.COLOMBIA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 90.COLOMBIA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 91.COLOMBIA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 92.TURKEY COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 93.TURKEY COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 94.TURKEY COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 95.REST OF LAMEA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 96.REST OF LAMEA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 97.REST OF LAMEA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 98.AEROGEN: COMPANY SNAPSHOT
  • TABLE 99.AEROGEN: PRODUCT PORTFOLIO
  • TABLE 100.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 101.ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 102.ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 01.BAXTER: COMPANY SNAPSHOT
  • TABLE 02.BAXTER: BUSINESS UNITS
  • TABLE 03.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 04.BOEHRINGER INGELHEIM: PRODUCT BUSINESS SEGMENTS
  • TABLE 05.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 06.3M: COMPANY SNAPSHOT
  • TABLE 07.3M: OPERATING BUSINESS SEGMENTS
  • TABLE 08.3M: PRODUCT PORTFOLIO
  • TABLE 09.GF HEALTH PRODUCTS: SNAPSHOT
  • TABLE 10.GF HEALTH PRODUCTS: PRODUCT PORTFOLIO
  • TABLE 11.GSK.: COMPANY SNAPSHOT
  • TABLE 12.GSK: OPERATING SEGMENTS
  • TABLE 13.GSK: PRODUCT PORTFOLIO
  • TABLE 14.PHILIPS: COMPANY SNAPSHOT
  • TABLE 15.PHILIPS: OPERATING SEGMENTS
  • TABLE 16.PHILIPS: PRODUCT PORTFOLIO
  • TABLE 17.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 18.NOVARTIS: OPERATING SEGMENTS
  • TABLE 19.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 20.PARI: COMPANY SNAPSHOT
  • TABLE 21.PARI: PRODUCT PORTFOLIO
  • TABLE 22.PARI: PRODUCT PORTFOLIO
  • TABLE 23.SMITHS MEDICAL: COMPANY SNAPSHOT
  • TABLE 24.SMITHS MEDICAL: OPERATING SEGMENTS
  • TABLE 25.SMITHS MEDICAL: PRODUCT PORTFOLIOG

LIST OF FIGURES

  • FIGURE 01.TOP FACTORS IMPACTING GLOBAL COPD AND ASTHMA DEVICES MARKET, 2015-2022
  • FIGURE 02.TOP INVESTMENT POCKETS OF GLOBAL COPD AND ASTHMA DEVICES MARKET, BY COUNTRY
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2016-2018*
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016-2018* (%)
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2016-2018* (%)
  • FIGURE 06.VALUE CHAIN ANALYSIS OF GLOBAL COPD AND ASTHMA DEVICES
  • FIGURE 07.PATENT REGISTRATIONS BY REGION 2011-2014 (%)
  • FIGURE 08.U.S. PATENT REGISTRATIONS, BY PRODUCT, 2011-2014 (%)
  • FIGURE 09.EUROPE PATENT REGISTRATIONS, BY PRODUCT 2011-2014 (%)
  • FIGURE 10.JAPAN PATENT REGISTRATIONS, BY PRODUCT, 2012-2014 (%)
  • FIGURE 11.THE FOLLOWING FIGURE DEPICTS THE PREVALENCE OF COPD AMONG PEOPLE AGED 45 AND ABOVE, BY AGE AND SEX (2017-2018).
  • FIGURE 12.COMPARATIVE SHARE ANALYSIS OF INHALERS ASTHMA COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF NEBULIZERS ASTHMA COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ASTHMA COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HOPSPITALS COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF HEALTHCARE PAYERS COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019 & 2027(%)
  • FIGURE 19.ASTRAZENECA: NET SALES, 2016-2018 ($THOUSAND)
  • FIGURE 20.ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 21.ASTRAZENECA: REVENUE SHARE BY REGION 2018 (%)
  • FIGURE 22.NET SALES, 2016-2018 ($MILLION)
  • FIGURE 23.BAXTER: REVENUE SHARE BY BUSINESS UNIT, 2018 (%)
  • FIGURE 24.BAXTER: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 25.BOEHRINGER INGELHEIM: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 26.BOEHRINGER INGELHEIM: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 27.BOEHRINGER INGELHEIM: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 28.3M: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 29.3M: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 30.3M: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 31.GSK: REVENUE, 2016-2018($MILLION)
  • FIGURE 32.GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 33.GSK: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 34.PHILIPS: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 35.PHILIPS: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 36.PHILIPS: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 37.NOVARTIS: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 38.NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 39.NOVARTIS: REVENUE SHARE BY REGION 2018(%)
  • FIGURE 40.SMITHS MEDICAL: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 41.SMITHS MEDICAL: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 42.SMITHS MEDICAL: REVENUE SHARE BY REGION, 2018 (%)